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ABSTRACT
Until recently, brain aspergillosis was almost
always fatal, with a response rate to amphotericin
B of < 10%. This study describes a retrospective
analysis of eight consecutive cases of brain
aspergillosis. All patients were immunosup-
pressed and five required mechanical ventilation.
Antifungal treatment included amphotericin B
(n = 7), itraconazole (n = 3), voriconazole (n = 2)
and flucytosine (n = 1). Three (38%) patients
survived following prolonged azole therapy after
initial amphotericin B treatment, combined with a
reduction in their immunosuppressive treatment.
The prognosis of brain aspergillosis might be
improved if immunosuppression could be
reduced and prolonged oral azole therapy used.
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Invasive aspergillosis is a major cause of morbid-
ity and mortality in immunosuppressed patients
[1–3]. In a cohort study in 1994–1995, complete or
partial responses were seen in 132 (40%) of 330
patients with pulmonary invasive aspergillosis,
and in 23 (16%) of 148 patients with disseminated
aspergillosis [1]. Central nervous system involve-
ment corresponded with the poorest response
rate, with complete or partial response reported in
three (9%) of 34 patients. A review in 1996
reported a crude mortality rate of 99% (140 ⁄ 141
patients) in cases of brain aspergillosis [4]. How-
ever, the development of new azoles active
against aspergillosis might improve this situation.
To investigate this possibility, eight consecutive
patients with brain aspergillosis admitted to the
Infectious Diseases intensive care unit (ICU) at
Bichat-Claude Bernard Hospital (a 1200-bed uni-
versity-affiliated teaching hospital that serves as a
referral centre in the metropolitan Paris area)
were analysed retrospectively.
Brain aspergillosis was defined by the three
following criteria: (1) at least one predisposing
condition for invasive aspergillosis (bone marrow
transplant, haematological malignancy, chronic
neutropenia, immunosuppressive treatment); (2)
at least one localised lesion visible on computer-
ised tomography brain scan and ⁄ or magnetic
resonance imaging in the absence of an alternative
diagnosis; and (3) isolation ofAspergillus spp. from
culture of intracerebral material, bronchoalveolar
lavage or sinus samples, or hyphae consistent with
the presence of Aspergillus spp. in a biopsy of brain
tissue. All patients had definite or probable inva-
sive aspergillosis according to the consensus
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guidelines of the European Organisation for
Research and Treatment of Cancer (EO-
RTC) ⁄National Institute of Health (NIH) ⁄Mycoses
Study Group (MSG) [5]. All patient charts and
radiographs were reviewed, and the patients’ sex,
age, predisposing factors, symptoms, Glasgow
Coma Scale (GCS) score and Simplified Acute
Physiology Score (SAPS) II [6,7] were recorded.
Surgical and medical treatment and the outcome
for each patient at the time of the most recent
evaluation, or on the basis of correspondence,
were recorded. Identification of Aspergillus spp.
was performed with the use of standard micro-
biological techniques [8].
All eight patients were immunosuppressed
(Table 1), and their mean age was 49.5 years
(range 46–64 years). Most (6 ⁄ 8) patients devel-
oped the first symptoms of brain aspergillosis
while hospitalised. Symptoms on first evaluation
included fever (n = 6), headache (n = 3), focal
neurological manifestations (n = 2) and seizures
(n = 1). The chest X-ray was abnormal for six
patients, including five patients with lesions
suggestive of pulmonary aspergillosis (nodular
shadows with and without cavitation). Initial
brain computerised tomography scans revealed
single (n = 3) or multiple (n = 4) lesions with a
median size of 2 cm (range 2–3 cm). Other radio-
logical features included peri-lesional oedema
(n = 4), mass effect (n = 3) and brain haemor-
rhage (n = 1). One patient with a normal brain
computerised tomography scan had 15 individual
lesions by magnetic resonance imaging. Two
patients underwent lumbar puncture; both had
elevated protein levels (0.7 and 1.2 g ⁄L), normal
glucose levels, and negative results for direct
examination and culture of cerebrospinal fluid.
One patient had an elevated white cell count
(1640 ⁄mm3; 95% neutrophils). Aspergillus fumiga-
tus was identified from all seven patients with a
positive culture (7 ⁄ 8).
Patients were transferred to the ICU mostly
because of neurological deterioration (n = 6). The
mean GCS score upon ICU admission was 11.5
(range 7.5–15) and the mean SAPS II score was 34
(21–46). Five (62%) patients died in the ICU,
mainly because of neurological deterioration
(4 ⁄ 5), including two patients who developed
brain stem herniation (one after lumbar puncture
was performed). The mean delay between ICU
admission and death was 12 days. Three patients
survived, with a mean duration of ICU stay of
43 days and a mean follow-up after discontinu-
ation of antifungal treatment of 3 years. These
Table 1. Characteristics of eight consecutive patients admitted to the intensive care unit with brain aspergillosis
Sex /Age
Underlying
disease Immunosuppression
Extra-cerebral
involvement
Aspergillus spp.
isolation
Antifungal
treatment
Surgical
treatment Outcome
Female
61 years
Acute
leukaemia
Myeloablative
chemotherapy
Lung BAL Ampho B
(31 days)
Flucytosine
(3 days)
None Died
Male
67 years
Kidney
transplant
Corticosteroids
Cyclosporin
Lung Brain abscess
aspiration
Ampho B
(25 days)
External
diversion
Died
Male
32 years
Chronic
myeloid
leukaemia
Bone marrow
allograft
None Brain biopsy
(autopsy)
Nonea None Died
Female
43 years
Glioblastoma Corticosteroids None Brain biopsy Ampho B
(14 days)
None Died
Female
67 years
Wegener
granulomatosis
Corticosteroids Lung BAL Ampho B
(29 days)
Itraconazole
(410 days)
None Cured
Male
49 years
Larynx cancer Myeloablative
chemotherapy
Lung BALa + brain
abscess
aspiration
Ampho B
(25 days)
Itraconazole
(13 days)
Abscess
aspiration
Died
Female
49 years
Systemic lupus
erythematosus
End-stage
renal disease
Corticosteroids Lung BAL Ampho B ⁄
liposomal
(44 days)
Voriconazole
Itraconazole
(380 days)
No Cured
Male
53 years
Wegener
granulomatosis
Corticosteroids Lung,
frontal sinus
Frontal sinus
aspiration
Ampho B
(28 days)
Voriconazole
(460 days)
No Cured
Ampho B, amphotericin B; BAL, bronchoalveolar lavage.
aThe diagnosis of brain aspergillosis was post-mortem.
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three patients received intravenous treatment
with deoxycholate amphotericin B, followed by
liposomal amphotericin B (mean duration of
33 days), followed by prolonged oral azole treat-
ment (mean duration of 14 months). For these
patients, immunosuppression could be reduced
by a dose reduction in their corticosteroid treat-
ment. Two of these patients had no neurological
sequelae at the time of last evaluation.
Although amphotericin B has been the main-
stay of treatment for invasive aspergillosis since
1959 [3,9], the superiority of voriconazole over
amphotericin B as initial therapy for invasive
aspergillosis in terms of response rate, survival
rate and safety has now been demonstrated [10].
Brain aspergillosis has a crude mortality rate
estimated to be between 90% and 99% in the
largest studies [1,4,11], and it may be this local-
isation that will benefit most from the develop-
ment of new azoles. Voriconazole could be the
preferred treatment for this indication, as it can be
given orally and has a good safety profile [12].
The superiority of voriconazole over amphoteri-
cin B for the initial treatment of invasive asper-
gillosis has been demonstrated in a large
randomised study [10], whereas a separate study
failed to show any significant advantage for itra-
conazole [13]. Voriconazole also has a favourable
pharmacokinetic profile, with good blood–brain
barrier penetration and a mean cerebrospinal
fluid concentration ⁄plasma concentration ratio
ranging from 0.22 to 1.0 [14,15], so that voricon-
azole levels were above the minimal fungicidal
concentration for Aspergillus spp. in most cere-
brospinal fluid specimens tested in one study [16].
Among the other drugs currently licensed for the
treatment of invasive aspergillosis, amphotericin
B and its lipid formulations, as well as itracon-
azole and caspofungin, are unable to achieve
consistently measurable concentrations in cere-
brospinal fluid. More clinical studies are needed
for other new azoles such as ravuconazole or
posaconazole.
The present study describes eight patients with
severe invasive aspergillosis, similar to those
described in previous series [3,11,17,18]. In addi-
tion to the brain localisation of their aspergillosis,
these patients were admitted to the ICU, which has
been associated with a mortality rate of 92%
[19,20]. In the present study, three patients had no
signs of aspergillosis relapse at 3 years following
the discontinuation of antifungal treatment. This
favourable outcome could be associated with their
potentially reversible immunosuppression and
their prolonged treatment with suppressive anti-
fungals. Thus, the prognosis for brain aspergillosis
might be improved if immunosuppression could
be reduced and prolonged oral azole therapy used.
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ABSTRACT
Sub-inhibitory concentrations of imipenem and
meropenem were evaluated for their ability to
induce morphological changes with six strains of
Acinetobacter baumannii isolated from patients
with nosocomial pneumonia. Three strains were
susceptible and three were resistant to carbapen-
ems. The strains were grown in the presence of 0
(controls), 0.25·, 0.5· and 1· the MIC of both
carbapenems for 4 h, and then examined after
Gram’s stain. Cells ‡ 3 lm in size (spheroplasts)
were considered to be altered. Both carbapenems
induced significant numbers of spheroplasts com-
pared to controls. Imipenem had more effect
against susceptible strains, while meropenem had
a greater effect against resistant strains.
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Various antimicrobial agents are known to retain
some activity at sub-MIC concentrations, causing
bacteria to undergo ultrastructural changes [1–3].
These changes promote opsonisation and phago-
cytosis [4–6], resulting in bacterial clearance by
the immune system, and explain, at least in part,
pharmacodynamic phenomena such as the post-
antibiotic effect [7]. Penicillins and cephalosporins
induce the formation of filamentous forms
because their primary target is penicillin-binding
protein 3 (PBP3) [1–3]. Several studies with
carbapenems have revealed the formation of
round cells (spheroplasts) with different species
of Gram-negative bacteria [8–11]. This differential
pattern has been explained by the affinity of
carbapenems for PBP2.
In the clinical setting, there are periods between
doses when the concentrations of antimicrobial
agents fall below the MICs for the infecting
bacteria; nevertheless most b-lactams will achieve
a bacteriological cure in many clinical scenarios,
provided that the concentration remains above the
MIC for ‡ 40% of the interval between doses;
indeed, this period may be even shorter (25–30%)
with carbapenems because of their prolonged
post-antibiotic effect [12]. Hence, the sub-MIC
actitivity (SMA) plays a significant role in antimi-
crobial therapy. This role may be of particular
relevance with multiresistant pathogens such as
Acinetobacter baumannii, which is now considered
to be one of the most important nosocomial
bacteria [13]. However, to our knowledge, there
are no data on the SMA of carbapenems against
A. baumannii. Therefore, the aim of the present
study was to assess the in-vitro SMA of imipenem
and meropenem against six clinical isolates of
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